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The hereditary liver disease, acute intermittent porphyria (ALP),  1 is characterized 
clinically by  a  disabling, sometimes lethal,  neurological-visceral symptom  complex 
and biochemically by excessive activity of the porphyrin-heme biosynthetic pathway 
(1-3).  The  mitochondrial  enzyme  6-aminolevulinate synthetase  (ALAS),  which  is 
rate limiting for this pathway (4), is found at high levels of activity in the  livers of 
AIP patients  (5,  6),  and  this accounts  for  the  excessive formation and  subsequent 
excretion into the urine of porphyrin precursors which characterizes the  disorder. 
The high levels of hepatic ALAS in AIP have been postulated to reflect an operator 
gene  defect  (5,  7,  8)  which  ultimately finds expression in  the  "over-production" of 
this enzyme. ALAS is, however, readily inducible in the liver by a  variety of drugs 
and foreign chemicals (9-11), and recent studies from these laboratories have demon- 
strated that many 5/3 steroid metabolites derived from hormones natural to man are 
also potent inducers of this enzyme (12-14). The occurrence of this endogenous class 
of  potent  inducers  of  ALAS raised  the  possibility that  AIP  patients  might  have 
abnormalities in steroid hormone biotransformation which lead to the disproportionate 
formation  of  5/3  metabolites from  precursor  compounds.  If  so,  such  steroids could 
contribute by an induction mechanism  to  the high levels of hepatic ALAS activity 
which  characterize AIP patients. 
To  explore this  possibility the  metabolic  fate  of  tracer  doses  of  testoster- 
one(A4-androstene-17/3-o[, 3-one)-4-~4C was  examined  in  15  patients with AIP 
and  compared  with  that  in  a  matched  control  group  of  12  normal  subjects. 
Testosterone was selected for initial study, since it is a  structural prototype of 
endogenous steroids which are normally transformed in man to approximately 
equal  quantities  of  5o~  and  5/3  metabolites;  thus  a  derangement  of  hormone 
metabolism in AIP in which one or the other pathway predominated could be 
readily ascertained. 
* These studies were supported in part by U.S. Public Health Service Grants CA-07304 and 
HD-04313 and General Clinical Research Center Grants RR-53 and RR-102. 
x Abbreviations used in this paper: AIP,  acute intermittent  porphyria;  ALAS, b-amino- 
levulinate synthetase; PCT, porphyria cutanea tarda. 
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The  results  of  these  studies  indicate  that  individuals  carrying  the  genetic 
lesion of AIP  display a  marked  abnormality  of testosterone  metabolism mani- 
fest by the  excessive reductive  transformation  of this compound  along the  5/3 
pathway,  the pathway  through  which metabolites having the potential  capac- 
ity for inducing ALAS in the liver are generated.  Studies with a  second steroid, 
dehydroisoandrosterone(AS-androstene-3B-ol,17-one)-4-1~C,  confirmed  the  de- 
feet  in  hormone  metabolism  demonstrated  with  l~C-labeled  testosterone  in 
the  AIP  patients.  The  enzymatic  basis  for  this  defect  will  be  described  in  a 
subsequent  report3  The  findings  in  this  study  clearly  establish  the  existence 
of  a  major  abnormality  of  hormone  biotransformation  in  AIP  and  support 
the  view  that  there  is  a  significant  interplay  of  endocrine  as  well  as  genetic 
factors  in  the  pathogenesis  of  this  hereditary  liver disease  (15,  16). 
Methods and Clinical Material 
Tracer Hormones.--Testosterone-4-14C and dehydroisoandrosterone4-14C  were purchased 
from the New England Nuclear Corp., Boston, Mass. Paper chromatography of an aliquot of 
each steroid indicated that the materials were >980./0 pure and they were used without further 
recrystallization  or  other purification.  The compounds  were dissolved in  sterile  redistilled 
propylene glycol at a concentration of approximately 106 cpm/ml, and weighed aliquots of the 
solution were assayed  to determine its exact specific  activity. Using a  Venopack and  a  28- 
guage butterfly needle, a slow 5% glucose-in-water intravenous infusion was started in each 
patient, and weighed portions of the propylene glycol solution were then injected slowly over 
a 10 rain period into the tubing just above the needle. This procedure serves to sweep the ste- 
roid solution intravenously and prevent loss of steroid by absorption to the polyethylene tubing 
(17). 
Three complete 24-hr urine collections were then obtained from each subject. In all studies 
the subject voided before the administration of the tracer and the collection was started from 
that  time.  Completeness of collections was judged by creatlnine determinations; studies in 
our laboratory have conclusively established that creatinine measurements are a reliable index 
of completeness of collection when adequate precautions are observed.  3 
The first 2-day collections, which invariably contained  the bulk  of the excreted radioac- 
tivity in all subjects, were combined and hydrolyzed by methods which we have described in 
details previously (18).  In the case of the dehydroisoandrosterone-4-14C  studies,  3  days of 
urine collections were combined before hydrolysis and  further  chemical analysis  since this 
steroid is excreted more slowly than testosterone in man.  The hydrolytic methods included 
adjustment of the urine to pH 5 after the addition of 10% v/v of an 0.3 ~ pH 5 acetate buffer 
solution and 300 Fishman units/ml of the enzyme fl-glucuronidase (Ketodase). After incuba- 
tion of the treated urine for 5 days at 37°C  the urine was extracted continuously with ethyl 
ether for 48  hr.  The ether extract was washed with  10%  NaOH and  saturated  brine until 
neutral and then dried and concentrated in vacuo. The residual urine and the aqueous washings 
of the ether extract were combined, acidified to 1 N in sulfuric acid, and again continuously 
extracted with ethyl ether for an additional 48 hr. The residual urine after this solvolysis and 
the aqueous washings  of  the latter extract were combined,  made 5% v/v in sulfuric acid, 
refluxed for 30 rain, and then extracted continuously with ethyl ether for a further 48 hr. This 
2 Bradlow, H. L., P. N.  Gillette, T. F. Gallagher, and A. Kappas.  Steroid studies in por- 
phyria. II. Evidence for a deficiency of steroid A4-5a-reductase activity in acute intermittent 
porphyria. Manuscript in [)reparation. 
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ether extract was washed, dried, and concentrated again as above. The neutral extracts were 
identified as glucuronide, sulfate, and hot acid extracts, respectively, according to the above 
procedures, and each of the three extracts was separated into ketonic and nonketonic fractions 
with Girard's "T" reagent. 
Paper chromatography of each of the ketonic fractions was carried out on 118  X  18 cm 
strips of Whatman No.  1 paper slit to give two 2.5-cm side strips for standards and dye in- 
dicators and two 5-cm strips for samples. After sample application, the strips were inserted into 
the tanks and run in appropriate systems without preequilibration until the dye marker was 
n  the lower portion of the strip. The side strips were sprayed to detect the concurrently run 
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FIG.  1.  Structures  of  testosterone and  the  two  principal metabolites,  androsterone and 
etiocholanolone, into which it is transformed in man. Stereochemical representations of these 
5or and 5fl metabolites arc shown at the bottom. The 5a derivative androsterone is planar like 
the parent hormone; the 5fl derivative etiocholanolone is highly angulated at the A:B ring 
junction. The black dots indicate the differing orientations of the C5 hydrogen atom in each 
type of metabolite. 
standards and the sample strips were scanned in a Vanguard 880 scanner to locate the radio- 
active peaks, which were identified by comparison with the standards. The radioactive peaks 
were then eluted with ethyl alcohol and counted to determine the coversion of the administered 
hormone to the various metabolites. For determination of the endogenous output of 17 keto- 
steroids, separate allquots of the ketonic extracts were chromatographed in the same manner. 
Etiocholanolone (5 fl-androstane-3a-ol, 17-one) and androsterone (5 o~-androstane-3o~-ol,  17- 
one)  were  located  as  described  above,  eluted,  and  quantitated  by  the  micro-Zimmerman 
reaction. All radioactive samples were counted in the Diotol scintillant of Herberg (19) using 
Butyl PBD as the phosphor in a Packard 3320 liquid scintillation  counter (Packard Instrument 
Co.,  Inc.,  Downers  Grove, Ill.).  Correction for quenching was  made by using the internal 
standard procedure. 
Fig.  1  depicts  the structures of  testosterone and  the  two principal  17-ketosteroids into 
which it is transformed in man; stereochemical representations of these 5fl and 5~ metabolites 
are also shown. 1046  STUDIES  ]N  PORPHYRIA 
A[P Patients.  A total of 15 patients with well defined hepatic porphyria of the AlP type 
were studied. The diagnosis in each case was established on the basis of characteristic clinical 
and biochemical findings (1-3);  t3q3ical values for the urinary excretion of porphyrins and 
precursors in the majority of these patients have been presented elsewhere (20). The age range 
of this patient group was 21-56 yr; the group comprised 12 women and 3 men. This is a some- 
what higher than the average female:male sex incidence of AIP (21) but comprises our full 
referral experience for this disease at The Rockefeller University Hospital. The majority of 
the steroid metabolism studies were carried out in the Clinical Research Center of this hospital 
with the subjects consuming an ordinary hospital diet. A control group which comprised 12 
normal individuals of the same sex incidence and approximate age range as the AIP patients 
was also studied. The majority of these subjects were also hospitalized and the tracer experi- 
ments were conducted under the same conditions as for the porphyrlc individuals. 
It is not possible to give a quantitative assessment to the clinical severity of the porphyric 
process in AIP patients since it is well known that the urinary output of intermediates in the 
TABLE  I 
Excretion  and  Metabolism  of  Testosterone-4J4C  in  Normal  Subjects  and  in  AlP  Patients 
Subjects  Urine 
Normal subjects  81 
(69-93) 
Group A AIP  76 
patients  (6485) 
Group B AIP  65 
patients  (44-89) 
Glucuro- 
nide 
fraction 
(4??57) 
41 
(3(>46) 
29 
(23-37) 
Sulfate 
fraction 
15 
(10-22) 
(¢_218) 
7 
(4-10) 
Hot acid 
fraction 
3 
(0-5) 
(2511 ) 
6 
(2  10) 
Androste- 
rone (So) 
26 
(22-35) 
(1020) 
(3-611 ) 
Etiochol- 
anolone 
(58) 
23 
(17-36) 
28 
(222-335) 
(10-30) 
Metabolite 
ratio, 
5~/5~ 
0.9:1 
3.3:1 
Data are expressed as per cent of administered dose of the 14C-labeled hormone; figures in 
parentheses represent the range of values. The average 5fl/5c~ metabolite ratio for the entire 
group of AIP patients is indicated. 
porphyrin-heme pathway does not necessarily correlate with the symptomatic state of the 
disease. Therefore, to facilitate interpretation of the data obtained in this study, the AIP 
patients were categorized into two principal groups based on qualitative assessment of the 
clinical  status of each subject at the time of and in the immediate months or years preceding 
the tracer experiment. Group A comprises 10  AIP patients who were either asymptomatic 
during  this period or  only  occasionally ill  with mild episodic abdominal cramps,  etc.  All 
subjects in this group were ambulatory and active, including school attendance or full-time 
work. Group B comprises five patients who suffered from chronic recurrent, frequently severe 
abdominal colic which was sufficiently disabling to prevent work, or had residual neurologic 
symptoms or muscular wasting from previous exacerbations of the disorder. The group  B 
patients were clearly distinguishable from the group A patients on the basis of history and 
clinical  symptoms or findings alone. 
RESULTS 
Normal Subjects.--The results of the testosterone-4-14C studies in the control 
group are recorded in Table I  and are entirely similar  to the data obtained in 
earlier  studies  of normal  individuals  in  these  laboratories  (22).  The  ratio  of KAPPAS,  BRADLOW,  GILLETTE,  AND  GALLAGtIER  1047 
5fl/Sa  metabolites  derived  from  the  exogenous  14C-labeled  hormone  ranged 
from 0.6:1  to 1.8:1  with a mean of 0.9:1.  The ratio of endogenously derived 
etiocholanolone (5/~) and androsterone (Sa) was similar (Table II). 
AIP  Subjects.- 
Group  A:  The  results  of the  testosterone-14C  studies  in  this  group  of  10 
patients are recorded in Table I. Excretion and hydrolysis of radioactive metab- 
olites of the  administered hormone in  these  subjects were within  the normal 
range. However the relative proportions of etiocholanolone and androsterone 
differed significantly with  the  average ratio of these 5/3 to 5a metabolites in 
the  AIP  subjects  being  substantially  higher  than  that  found  in  the  control 
subjects (Table I). 
Group  B:  This group of five AIP patients was characterized by a  normal 
TABLE  II 
Excretion of Dehydroisoandrosterone, Androsterone, and Etiooholanolone from  all Endogenous 
Sources in  lg Normal  Subjects and  in 12 AlP Patients 
Subjects  Dehydroisoandro-  Androsterone  (5~x)  Etiocholanolone  Metabolite  ratio, 
sterone  (5¢~)  5fl/5o~ 
Normal subjects  0.6  1.8  2.0  1.1 : 1 
(0.1-2.9)  (0.3-3.4)  (0.5-6.5) 
AIP patients  0.3  0.5  1.8  3.6:1 
(0.1-0.7)  (0.1-1.1)  (0,3-4.0) 
Data are expressed as mean values, with range in parentheses, of output in milligrams per 
day per gram creatinine. The ratio of endogenously formed 53 and 5~x metabolites in the 
AIP group was comparable to the ratio produced from the exogenously administered radio- 
labeled hormone (Table I). 
to low urinary excretion of administered radioactivity, significantly diminished 
glucuronide fraction (AIP mean 29 % vs. normal mean 50%),  and  slightly  de- 
creased  sulfate  fraction  (Table  I).  The  recovery of  "androsterone  plus  etio- 
cholanolone" was low (AIP mean 29% vs. normal mean 49 %),  with a  marked 
decrease in the output of the 5a compound. The mean 5/3/5a ratio of the group 
B AIP patients was somewhat higher than in the group A patients, the average 
5~/5~ ratio of the entire group of 15 AIP subjects exceeding the normal aver- 
age by  approximately 350%.  The  ratio  of endogenously  derived  5/3  and  5o~ 
derivatives in the AIP patients  (Table II) was comparable to that produced 
from the  administered  l~C-labeled hormone  (Table  I). 
In Fig. 2 are plotted the individual 5/~/5oz metabolite ratios for all of the nor- 
mal AIP subjects studied;  in  addition,  the 53/5oz ratios in five patients  with 
the  acquired form of hepatic porphyria,  porphyria cutanea tarda  (PCT),  are 
shown for comparative purposes. Detailed studies  of steroid hormone metab- 
olism  in  these  PCT  patients  will  be  reported  elsewhere. 1048  STUDIES  IN  PORPtIYRIA 
DISCUSSION 
The data reported here indicate that AIP patients as a group have a signifi- 
cant abnormality of steroid hormone metabolism manifest by the  dispropor- 
tionate metabolism of the prototype hormone testosterone along the  5~ path- 
way. The mean ratio of 5t8/5a metabolites derived from the tracer dose of the 
hormone in the AIP subjects exceeded the average in normals by about 350 %, 
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FIG. 2.  The ratios of 5fl and 5c~ metabolites formed from testosterone4-14C in each of 12 
normal subjects, 15 AIP patients, and 5 individuals with the acquired form of hepatic par- 
phyria, PCT. 
with the individual 5/~/5c~ ratios in each of the 15 patients ranging from approx- 
imately 50% to as much as 1000% above the normal mean ratio. The highest 
ratio (9.0:1) was found in an asymptomatic AIP patient and is a 5/~/5~  ratio 
which we have never observed previously in any except severely myxedemetous 
individuals  (23).  The  pattern  of biotransformation of the  tracer-labeled hor- 
mone  was  also  clearly  representative  of  the  manner  in  which  structurally 
related  endogenous  hormones  were  metabolized,  since  the  5fl/5oz ratios  of 
metabolites  from endogenous  (Table  II)  and  exogenous hormones  (Table  I) 
were similar in the AIP patients.  Comparable studies with the second proto- 
type  hormone,  dehydroisoandrosterone-4-1*C,  confirmed  this  point  as  well. 
This hormone differs from testosterone in that the C-17 substituent is a ketone KAPPAS,  BRADLOW,  GILLETTE~  AND  GALLAGI-IER  1049 
rather than a hydroxyl group; the C-3 substituent is a 3/3-hydroxyl rather than 
a  ketone;  and the  double bond at  the A:B  ring junction  is between  C5  and 
C6  rather than C4  and C5.  Despite these structural  differences,  its reductive 
transformation at the A:B ring junction markedly favored the cis or 5[3 con- 
figuration,  as was the case with testosterone, in the AIP patients. 
It should be noted that no excess in production of dehydroisoandrosterone 
itself was observed in this study (Table II), as was earlier reported by Gold- 
berg et al. (24); rather, the principal abnormality defined in the isotope experi- 
ments  with  this  hormone  and  with  testosterone  was  characterized  by  the 
marked preferential metabolism of these compounds along the 5/3 pathway. 
An  attempt to relate 5/3/5a ratios in patients  to specific effects of a  given 
disease or therapeutic regimen are only meaningful if careful consideration is 
given to those factors which  can alter the ratio in such  a  way as to obscure 
any specific disease-related  effects. As has been recently reported by Zumoff 
et al.  (25), the 5fl/5a ratio can be altered by age and illness. With increasing 
age the 5/3/5a ratio becomes elevated in both men and women; the apparent 
effect  of nonspecific  chronic  illness  on  this  ratio  is  even  more  pronounced. 
In both sexes the  ratio becomes elevated primarily because  of a  decrease in 
the excretion of androsterone and a  lower total recovery of administered iso- 
tope  as  the  sum  of  the  two  compounds,  androsterone  plus  etiocholanolone. 
Studies with labeled androsterone and with androsterone sulfate have demon- 
strated a low urinary recovery of the administered compounds in the form of 
androsterone in chronically ill patients (26), suggesting that the elevated 5/3/5a 
ratios  in  such  individuals  represent  a  diversion  of  androsterone  to  other  as 
yet unidentified metabolites rather than a decreased formation of androsterone 
per se. This nonspecific effect of chronic illness no doubt includes a substantial 
contribution  arising  from the  effects of the  numerous drugs  which  such  pa- 
tients receive (25).  In order to demonstrate that there is, in a specific  disease 
state, an alteration in the relative reduction of a precursor hormone  to 5/3 and 
5a metabolites, it is necessary to establish that its over-all conversion  to an- 
drosterone  plus  etiocholanolone  is  in  the  normal  range  and  to  show  that  a 
chance  age effect in  the  given patient  population  is not  a  factor.  These re- 
quirements have been met in  the present study. The over-all excretion  of iso- 
topically labeled compounds, the extent of glucuronide formation, and  the re- 
covery as androsterone plus etiocholanolone were in the normal range for the 
great majority of the AIP patients studied  (i.e.,  in all the group A  patients) 
though not for the five chronically ill patients in group B  (Table I).  Further, 
these  patients  were restricted,  of course,  in  their  drug  usage because  of the 
provocative effects which  many drugs have on their disease; drug effects on 
the 5/3/5a ratio can therefore be excluded. The findings in the asymptomatic or 
only mildly  ill  AIP  patients  (group  A)  particularly  emphasize  these  points 
since these patients displayed a  substantial  increase in the 5/3/5o~ metabolite 
ratio (Table I) with normal recoveries of isotope as androsterone plus etiochol- 1050  STUDIES  IN  IPORPHYRIA 
anolone. The ages of these patients also eliminate any important age-related 
effect on this ratio. While the 5~/5oe ratios observed in the chronically ill AIP 
patients were comparable to those found in other (i.e., non-AIP)  chronically 
ill individuals (25), the ratios between the group A and group B AIP patients 
were in fact not substantially different despite the poor glucuronidase hydrolysis 
and low  recovery of isotope in the latter individuals. Finally, the low 513/5o~ 
ratios observed in patients with the acquired form of hepatic porphyria, PCT, 
(Fig. 2) make it clear that the high  ratios found ill the  genetic form of the 
disease  are  distinctive  of  this  disorder  and  not  secondary to  the  porphyric 
process itself. The extremely high ratio  (9:0/1)  found in one asymptomatic 
AIP subject (Fig. 2) also suggests that the preferential formation of 53 metab- 
olites is not a consequence of the active disease state, per se, even in AIP. 
The  possible  pathogenetic significance  of  these  findings  merits  comment. 
Individuals  carrying the  genetic lesion  of AIP  are  well known  to be highly 
susceptible to the provocative effects of many exogenous chemicals, i.e. drugs, 
etc., which induce ALAS in liver cells.  Our previous studies have shown that 
5~  steroids,  which  are  natural  substances,  are  also  potent  inducers  of this 
enzyme experimentally. The excessive generation of 5j8 steroids from precursor 
hormones in AIP patients may thus be viewed as constituting an endogenous 
source of chemicals which have the potential for contributing, bv an induction 
mechanism,  to the high levels of ALAS  activity found in  the  livers of such 
patients. It is  emphasized that  the derangement in hormone metabolism de- 
scribed here is not unique to AIP, but may also be found in profound hypo- 
thyroidism (23). The postulated inducing action of 5# steroids in AIP  must 
therefore be contingent upon the associated genetic defect(s) in control of the 
heine pathway which underlies the extreme susceptibility of hepatic ALAS in 
this disorder to induction by various endogenous as well as exogenous chemi- 
cals (27-31). This steroid action is probably also dependent upon other factors, 
such as the activities of steroid conjugation or deconjugation mechanisms in 
the  liver, the  efficiency of excretory processes,  etc.,  which can influence the 
availability or  the  access  of free 5~  steroids  to inducing  sites  for ALAS in 
hepatic cells  (32). It is not evident at present whether the abnormal hormone 
metabolism demonstrated in  AIP is  acquired in some fashion or h~  partial 
genetic  determinants  itself; nor  is the specific relationship  between the deg- 
radative  pathway  for  steroid hormones  and  the  biosynthetic  pathway  for 
porphyrins and heme clear. The extent and consistency with which significant 
derangements  of both  of these pathways  are  demonstrable in  AIP  patients, 
however, strongly suggests that there is  an important interplay of endocrine 
as well as genetic factors in the pathogenesis of this hereditary liver disease. 
SUMMARY 
A variety of 53 steroid metabolites derived from hormones natural  to  man 
are potent inducers experimentally of &aminolevulinate  synthetase,  the rate- KAPPAS,  BRADLOW~ GILLETTE,  AND  GALLAGHER  1051 
limiting enzyme in  porphyrin-heme formation.  This  mitochondrial  enzyme  is 
found at high levels of activity in the livers of patients  with  the  genetic  dis- 
ease, acute intermittent porphyria (AIP). In this study the metabolism of 14C- 
labeled testosterone was examined in AIP patients to determine whether there 
was a  disproportionate conversion of the hormone to its 5~,  compared to its 
5a metabolite. The results indicate that AIP subjects do generate a substan- 
tially  greater  than  normal  fraction  of  5/3  metabolite  from this  steroid;  the 
excessive degree  of ring  A  reduction  of testosterone taking place via the  5/3 
pathway in  the  porphyric patients  averages 350%  greater than  in  the  non- 
porphyric  subjects.  In  one  asymptomatic AIP  patient  the  disproportionate 
generation  of 5/3 metabolite from the  hormone reached  a  level  10  times  the 
normal  mean.  Studies  with  a  second 14C-labeled  hormone,  dehydroisoandros- 
terone,  whose  metabolism in  man  resembles that  of testosterone,  confirmed 
the  derangement  in  reductive  transformation  of steroids  found  in  the  indi- 
viduals  carrying  the  genetic  lesion  of AIP. 
These  findings  define  a  new  endocrine  abnormality  in  AIP  patients  and 
raise the possibility that endogenously derived 5~ steroids may contribute by an 
induction mechanism to the increased levels of hepatic 8-aminolevulinate syn- 
thetase activity found in AIP patients. 
The authors are indebted to the Misses G. Gilman, N. Hellinger, and R. Jandorek for ex- 
cellent technical assistance and to Miss Ann Marie Quatela for the preparation of this manu- 
script. 
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